Cardiotoxicity and other Late effects After Radiotherapy and ImmunochemoTherapy in Non-Hodgkin lYmphoma - CLARITY

ederlands Kanker Instituut0 个研究点目标入组 525 人开始时间: 待定最近更新: 2024年4月15日

适应症

试验速览

暂无简介。

•In order to be eligible to participate in this study, a subject must meet the
•following criteria.
•* 350 survivors of mediastinal large B*cell non-Hodgkin lymphoma (ICD-code
•9679) or diffuse large B-cell non-Hodgkin lymphoma (ICD-code 9684), treated
•with at least five cycles of (R-)CHOP (250 mg/m2 anthracyclines or more) or
•treated with a combination of mediastinal radiotherapy and anthracyclines
•(independent of dose).
•o 200 survivors treated between five to thirteen years ago (2007-2015)
•o 150 survivors treated between thirteen to eighteen years ago (2002-2007)
•* The survivors were treated in one of the following centers, participating in
•the BETER-consortium: Amsterdam UMC (location VUmc or AMC), EMC, UMCU, UMCG,
•UMC Radboud or ASZ.
•* Age at diagnosis 15 up to 60 years.
•* Age at the time of inclusion: younger than 75 years old., Comparison group:
•* 175 siblings of the above mentioned patients with their date of birth closest
•to the birthdate of the survivor.

•A potential subject who meets any of the following criteria will be excluded
•from participation in this study:
•* Use of immunosuppressant and/or prednisolone
•* HIV-infected individuals
•* Pregnant women
•* Mental disability or psychological condition potentially hampering compliance
•with the study protocol
•* Insufficient understanding of the Dutch language

发起方

ederlands Kanker Instituut